...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition

How about management being telling us why the enterprise value went form $125 million to $500 million is 2 months, There must be a very very good reason other than that the phase 1 trial 3694 is working well to this point,   I am just speculation but is it possible a pharma has knocked on the door and wants a partnership and that is why we had that cancellation of the AGM last september??

How long does it take to get a deal done if that is the case?????  Maybe I am just dreaming

Share
New Message
Please login to post a reply